Organogenesis (ORGO) Stock Price, News & Analysis

Company Overview

Organogenesis Inc. operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures. These products are supported by clinical data demonstrating efficacy in accelerating wound closure and improving patient outcomes in both inpatient and outpatient settings.

Headquartered in Canton, Massachusetts, Organogenesis maintains manufacturing and distribution capabilities in North America with a network of clinical and commercial operations aimed at expanding access to advanced wound care and regenerative therapies. The company continues to invest in research and development to broaden its product pipeline and pursue collaborations that enhance its position in the global regenerative medicine market.

Key Stats

• Today's Range: $4.89 to $5.09
• 50-Day Range: $4.03 to $5.15
• 52-Week Range: $2.61 to $6.71
• Volume: 731,186 shs
• Average Volume: 742,392 shs
• Market Capitalization: $625.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Moderate Buy

Organogenesis Stock Analysis - MarketRank™

Organogenesis scored higher than 80% of companies evaluated by MarketBeat, and ranked 226th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Organogenesis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Organogenesis has a consensus price target of $7.50, representing about 52.1% upside from its current price of $4.93.

Amount of Analyst Coverage

Organogenesis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Organogenesis are expected to grow in the coming year, from ($0.07) to ($0.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organogenesis is -35.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organogenesis is -35.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Organogenesis has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.22% of the float of Organogenesis has been sold short.

Short Interest Ratio / Days to Cover

Organogenesis has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Organogenesis has recently increased by 3.98%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organogenesis does not currently pay a dividend.

Dividend Growth

Organogenesis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.01

Percentage of Shares Shorted

17.22% of the float of Organogenesis has been sold short.

Short Interest Ratio / Days to Cover

Organogenesis has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Organogenesis has recently increased by 3.98%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.55

News Sentiment

Organogenesis has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Organogenesis this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ORGO on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

MarketBeat Follows

1 people have added Organogenesis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organogenesis insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.00% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

49.57% of the stock of Organogenesis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ORGO Stock Analysis - Frequently Asked Questions

How have ORGO shares performed this year?

Organogenesis' stock was trading at $3.20 at the beginning of the year. Since then, ORGO stock has increased by 54.1% and is now trading at $4.93.

How were Organogenesis' earnings last quarter?

Organogenesis (NASDAQ:ORGO) announced its earnings results on Thursday, August, 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.08. The firm had revenue of $101.01 million for the quarter, compared to analyst estimates of $104.75 million. Organogenesis had a negative net margin of 1.92% and a negative trailing twelve-month return on equity of 0.37%.
Read the conference call transcript.

Who are Organogenesis' major shareholders?

Organogenesis' top institutional shareholders include Soleus Capital Management L.P. (9.73%), First Light Asset Management LLC (5.34%), Assenagon Asset Management S.A. (2.25%) and Acadian Asset Management LLC (1.91%). Insiders that own company stock include Albert Erani, Gary S Gillheeney, Lori Freedman, Michael Joseph Driscoll and Michael W Katz.
View institutional ownership trends.

How do I buy shares of Organogenesis?

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organogenesis investors own include NVIDIA (NVDA), Financial Select Sector SPDR Fund (XLF), Enterprise Products Partners (EPD), Advanced Micro Devices (AMD), Energy Transfer (ET), Moderna (MRNA) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORGO
• CIK: 1661181
• Web: organogenesis.com
• Phone: (781) 575-0775
• Fax: N/A
• Employees: 950
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Organogenesis: $7.50
• High Price Target: $9.00
• Low Price Target: $6.00
• Potential Upside/Downside: +52.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $860 thousand
• Net Margins: -1.92%
• Pretax Margin: -5.01%
• Return on Equity: -0.37%
• Return on Assets: -0.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.95
• Quick Ratio: 3.45

Sales & Book Value

• Annual Sales: $429.31 million
• Price / Sales: 1.46
• Cash Flow: $0.20 per share
• Price / Cash Flow: 24.15
• Book Value: $2.09 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 126,858,000
• Free Float: 84,995,000
• Market Cap: $625.41 million
• Optionable: Optionable
• Beta: 1.75